Summit Therapeutics PLC (SMMT) witnessed a surge of 5.14% during the intraday trading session on Friday, reflecting the positive sentiment following Goldman Sachs' initiation of coverage on the stock.
Goldman Sachs analyst Salveen Richter initiated coverage on Summit Therapeutics with a Buy rating and a price target of $42. The analyst is optimistic about the potential of Summit's lead drug candidate, ivonescimab, which is currently undergoing clinical trials for the treatment of Duchenne muscular dystrophy (DMD).
Analysts believe that if the trials for ivonescimab prove successful, it could potentially become a game-changer in the treatment of DMD, a rare genetic disorder characterized by progressive muscle degeneration. The positive coverage from a prominent investment bank like Goldman Sachs has boosted investor confidence in Summit Therapeutics, driving the stock price higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.